Literature DB >> 11422435

Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up.

R Moretti, P Torre, R M Antonello, G Cazzato.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11422435     DOI： 10.1046/j.1468-1331.2001.00224.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN： 1351-5101            Impact factor:   6.089


× No keyword cloud information.
  15 in total

1.  Donepezil in vascular dementia : a neurosonological and neuropsychological study.

Authors:  Cristina Paci; Rocco Di Mascio; Roberto Gobbato; Terenzio Carboni; Sandro Sanguigni; Stefania Sobrini; Vittoria Urbano; Federico Olivieri; Luigi Curatola
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

2.  Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease.

Authors:  Dong-Churl Suh; Simu K Thomas; Elmira Valiyeva; Stephen Arcona; Lien Vo
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  Cholinesterase inhibitors and vascular dementia: another string to their bow?

Authors:  Roger Bullock
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 4.  Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.

Authors:  Juan Wang; Hai-Yan Zhang; Xi-Can Tang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

Review 5.  Diagnosis and management of vascular cognitive impairment.

Authors:  David L Nyenhuis; Philip B Gorelick
Journal:  Curr Atheroscler Rep       Date:  2007-10       Impact factor: 5.113

6.  On the inhibitory affect of some dementia drugs on DNA polymerase Beta activity.

Authors:  V N Vyjayanti; N S Chary; Kalluri Subba Rao
Journal:  Neurochem Res       Date:  2008-01-10       Impact factor: 3.996

Review 7.  Vascular dementia.

Authors:  Amos D Korczyn; Veronika Vakhapova; Lea T Grinberg
Journal:  J Neurol Sci       Date:  2012-05-08       Impact factor: 3.181

Review 8.  Cholinergic dysfunction in vascular dementia.

Authors:  Gustavo C Román
Journal:  Curr Psychiatry Rep       Date:  2005-03       Impact factor: 8.081

9.  Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline.

Authors:  Moussa B H Youdim
Journal:  Exp Neurobiol       Date:  2013-03-31       Impact factor: 3.261

Review 10.  Rivastigmine in the treatment of Alzheimer's disease: an update.

Authors:  Maria Luisa Onor; Marianna Trevisiol; Eugenio Aguglia
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.